

Encl: As above

ANNEXURE – A

**FINANCIAL INFORMATION RELATING TO PAYMENT OF DIVIDEND BASIS
AUDITED FINANCIALS FOR THE YEAR ENDED MARCH 31, 2015**

| Particulars | Financial Year 2014-15 (amount in INR) | Financial Year 2013-14 (amount in INR) |
|--|---|---|
| Total Turnover | 1,179,256,828 | 1,083,783,455 |
| EBITDA | 75,273,149 | 89,092,734 |
| Depreciation | 27,117,599 | 19,927,110 |
| Profit Before Tax | 116,708,681 | 130,735,606 |
| Tax | 40,114,078 | 45,157,759 |
| Profit After Tax | 76,594,603 | 85,577,847 |
| Amounts appropriated from reserves, capital profits, accumulated profits of past or other special sources. | Nil | Nil |



**Auditor's Report On Quarterly Financial Results and Year to Date Results of the Company
Pursuant to the Clause 41 of the Listing Agreement**

To
Board of Directors of
Fortis Malar Hospitals Limited

1. We have audited the quarterly financial results of Fortis Malar Hospitals Limited for the quarter ended March 31, 2015 and the financial results for the year ended March 31, 2015, attached herewith, being submitted by the Company pursuant to the requirement of Clause 41 of the Listing Agreement, except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. The quarterly financial results are the derived figures between the audited figures in respect of the year ended March 31, 2015 and the published year-to-date figures up to December 31, 2014, being the date of the end of the third quarter of the current financial year, which were subject to limited review. The financial results for the quarter ended March 31, 2015 have been prepared on the basis of the financial results for the nine-month period ended December 31, 2014, the audited annual financial statements as at and for the year ended March 31, 2015, and the relevant requirements of Clause 41 of the Listing Agreement and are the responsibility of the Company's management and have been approved by the Board of Directors of the Company. Our responsibility is to express an opinion on these financial results based on our review of the financial results for the nine-month period ended December 31, 2014 which was prepared in accordance with the recognition and measurement principles laid down in Accounting Standard (AS) 25, Interim Financial Reporting, specified under Section 133 of the Companies Act, 2013 read with rule 7 of the Companies (Accounts) Rules, 2014 and other accounting principles generally accepted in India; our audit of the annual financial statements as at and for the year ended March 31, 2015; and the relevant requirements of Clause 41 of the Listing Agreement.
2. We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.
3. In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results as well as the year to date results:
 - i. are presented in accordance with the requirements of clause 41 of the Listing Agreement in this regard; and
 - ii. give a true and fair view of the net profit and other financial information for the quarter ended March 31, 2015 and for the year ended March 31, 2015.



S.R. BATLIBOI & ASSOCIATES LLP


Chartered Accountants

4. Further, read with paragraph 1 above, we report that the figures for the quarter ended March 31, 2015 represent the derived figures between the audited figures in respect of the financial year ended March 31, 2015 and the published year-to-date figures up to December 31, 2014, being the date of the end of the third quarter of the current financial year, which were subjected to a limited review as stated in paragraph 1 above, as required under Clause 41(I)(d) of the Listing Agreement.
5. Further, read with paragraph 1 above, we also report that we have, on the basis of the books of account and other records and information and explanations given to us by the management, also verified the number of shares as well as percentage of shareholdings in respect of aggregate amount of public shareholdings, as furnished by the company in terms of clause 35 of the Listing Agreement and found the same to be correct.

For S.R. BATLIBOI & ASSOCIATES LLP

Chartered Accountants

ICAI Firm registration number: 101049W



per Aniruddh Sankaran

Partner

Membership No.: 211107

Place: Chennai

Date: April 29, 2015



FORTIS MALAR HOSPITALS LIMITED
 Regd. Office: Escorts Heart Institute and Research Centre, Okhla Road, New Delhi - 110025
AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2015

| PART-I | Particulars | Standalone Quarter ended | | | | Standalone year ended | | | | (Rs. in lakhs except EPS and shareholding data) | |
|---------|--|---|---|--|---|---|---|---|---|---|----------------|
| | | March 31, 2015 | December 31, 2014 | March 31, 2014 | March 31, 2014 | March 31, 2015 | March 31, 2014 | March 31, 2015 | March 31, 2014 | March 31, 2015 | March 31, 2014 |
| | | (Refer Note 4) | (unaudited) | (Refer Note 4) | (Audited) | (Audited) | (Audited) | (Audited) | (Audited) | (Audited) | (Audited) |
| 1 | a) Income from Operations b) Other Operating Income Net Income from Operations | 3,079.57 (33.39) 3,046.18 | 3,075.10 15.68 3,090.78 | 2,702.16 38.77 2,740.93 | 10,770.01 67.82 10,837.83 | 11,763.92 28.65 11,792.57 | 11,763.92 28.65 11,792.57 | 10,770.01 67.82 10,837.83 | 11,763.92 28.65 11,792.57 | 10,770.01 67.82 10,837.83 | |
| 2 | a) Drugs and Consumables b) Employees Cost c) Professional Charges-Doctors d) Clinical Establishment Fee e) Net Depreciation and amortization f) Other Expenditure Total Expenditure | 735.31 382.48 741.70 449.02 75.45 499.79 2,883.75 | 710.92 404.03 787.70 451.49 67.57 516.75 2,938.46 | 589.46 312.00 684.27 417.56 199.27 422.48 2,477.82 | 2,452.48 1,395.14 2,675.39 1,667.26 199.27 1,756.63 10,143.47 | 2,755.35 1,547.42 2,954.38 1,762.34 271.18 2,023.15 11,309.40 | 2,755.35 1,547.42 2,954.38 1,762.34 271.18 2,023.15 11,309.40 | 2,452.48 1,395.14 2,675.39 1,667.26 199.27 1,756.63 10,143.47 | 2,755.35 1,547.42 2,954.38 1,762.34 271.18 2,023.15 11,309.40 | 2,452.48 1,395.14 2,675.39 1,667.26 199.27 1,756.63 10,143.47 | |
| 3 | Profit from operations before other income, interest & exceptional items (1-2) | 162.43 | 152.32 | 263.11 | 694.36 | 483.17 | 694.36 | 694.36 | 483.17 | 694.36 | |
| 4 | Other Income | 187.63 | 185.49 | 169.15 | 764.29 | 736.41 | 764.29 | 764.29 | 736.41 | 764.29 | |
| 5 | Profit before interest & Exceptional Items (3 + 4) | 350.06 | 337.81 | 432.26 | 1,384.61 | 1,217.96 | 1,384.61 | 1,384.61 | 1,217.96 | 1,384.61 | |
| 6 | Finance Cost | 9.31 | 10.14 | 9.98 | 45.73 | 50.88 | 45.73 | 45.73 | 50.88 | 45.73 | |
| 7 | Profit from ordinary activities after Finance Cost but before Exceptional items and Tax (5-6) | 340.75 | 327.67 | 422.28 | 1,338.88 | 1,167.08 | 1,338.88 | 1,338.88 | 1,167.08 | 1,338.88 | |
| 8 | Exceptional Items | - | - | 422.28 | - | - | - | - | - | - | |
| 9 | Profit from Ordinary Activities Before Tax | 340.75 | 327.67 | 422.28 | 1,338.88 | 1,167.08 | 1,338.88 | 1,338.88 | 1,167.08 | 1,338.88 | |
| 10 | Tax expense | 116.51 | 111.39 | 143.51 | 410.41 | 401.14 | 410.41 | 410.41 | 401.14 | 410.41 | |
| 11 | Net Profit from ordinary activities after Tax | 224.24 | 216.28 | 278.77 | 855.78 | 765.94 | 855.78 | 855.78 | 765.94 | 855.78 | |
| 12 | Extraordinary items | - | - | - | - | - | - | - | - | - | |
| 13 | Net Profit after tax | 224.24 | 216.28 | 278.77 | 855.78 | 765.94 | 855.78 | 855.78 | 765.94 | 855.78 | |
| 14 | Paid up Equity Share Capital (Face Value Rs.10 each) | 1,860.95 | 1,860.95 | 1,860.95 | 1,860.95 | 1,860.95 | 1,860.95 | 1,860.95 | 1,860.95 | 1,860.95 | |
| 15 | Reserves excluding Revaluation Reserves | - | - | - | 6,561.96 | 7,184.75 | 6,561.96 | 6,561.96 | 7,184.75 | 6,561.96 | |
| 16 | Earnings Per Share (EPS) - Basic (Rs.) | 1.20 | 1.16 | 1.50 | 4.80 | 4.12 | 4.80 | 4.80 | 4.12 | 4.80 | |
| 17 | Earnings Per Share (EPS) - Diluted (Rs.) | 1.20 | 1.16 | 1.50 | 4.80 | 4.10 | 4.80 | 4.80 | 4.10 | 4.80 | |
| PART-II | | [Not Annualised] | [Not Annualised] | [Not Annualised] | [Annualised] | [Annualised] | [Annualised] | [Annualised] | [Annualised] | [Annualised] | |
| A | PARTICULARS OF SHARE HOLDINGS | | | | | | | | | | |
| 1 | Public Shareholding | 6,841,857 | 6,841,857 | 6,841,857 | 6,841,857 | 6,841,857 | 6,841,857 | 6,841,857 | 6,841,857 | 6,841,857 | |
| | - Number of Shares | 36.80% | 36.80% | 36.80% | 36.80% | 36.80% | 36.80% | 36.80% | 36.80% | 36.80% | |
| 2 | Promoters and promoters group Shareholding | Nil | Nil | Nil | Nil | Nil | Nil | Nil | Nil | Nil | |
| | a) Pledged / Encumbered | | | | | | | | | | |
| | - No. of shares | | | | | | | | | | |
| | - % of shares (as a % of total shareholding of promoter and promoter group) | | | | | | | | | | |
| | b) Non-Encumbered | | | | | | | | | | |
| | - No. of shares | | | | | | | | | | |
| | - % of shares (as a % of total shareholding of promoter and promoter group) | | | | | | | | | | |
| | - % of shares (as a % of total share capital of the company) | | | | | | | | | | |
| B | INVESTOR COMPLAINTS | | | | | | | | | | |
| | Quarter ended March 31, 2015 | | | | | | | | | | |
| | Particulars | | | | | | | | | | |
| | Pending at the beginning of the quarter | | | | | | | | | | |
| | Received during the quarter | 11 | | | | | | | | | |
| | Disposed off during the quarter | 11 | | | | | | | | | |
| | Remaining unresolved at the end of the quarter | | | | | | | | | | |



1 STATEMENT OF ASSETS AND LIABILITIES

| Particulars | Standalone | | Consolidated | |
|----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|
| | As at March 31, 2015 (Audited) | As at March 31, 2014 (Audited) | As at March 31, 2015 (Audited) | As at March 31, 2014 (Audited) |
| I. EQUITY AND LIABILITIES | | | | |
| Shareholders' funds | | | | |
| Share capital | 9,045.70 | 8,422.91 | 9,124.05 | 8,481.02 |
| Reserves and surplus | 1,860.95 | 1,860.95 | 1,860.95 | 1,860.95 |
| Non-current liabilities | 7,184.75 | 6,561.96 | 7,263.10 | 6,620.07 |
| Deferred tax liabilities (net) | 22.65 | 74.26 | 22.85 | 74.26 |
| Long term provisions | - | - | - | - |
| Current liabilities | 1,925.69 | 1,575.05 | 1,946.11 | 1,594.51 |
| Trade payables | 1,317.19 | 1,028.56 | 1,319.28 | 1,030.64 |
| Other current liabilities | 423.72 | 377.10 | 439.06 | 392.45 |
| Short-term provisions | 184.78 | 169.39 | 187.77 | 171.42 |
| Total | 10,994.04 | 10,072.22 | 11,092.81 | 10,149.79 |
| II. ASSETS | | | | |
| Non-current assets | | | | |
| Tangible assets | 1,881.36 | 1,863.97 | 1,991.90 | 1,974.01 |
| Intangible assets | 1,756.02 | 1,743.33 | 1,756.02 | 1,743.33 |
| Capital work in progress | 14.71 | 19.83 | 14.71 | 19.83 |
| Non-current investments | 64.23 | 64.23 | 64.23 | 64.23 |
| Deferred tax asset (net) | 5.00 | 5.00 | - | - |
| Long term loans and advances | 41.40 | 31.58 | 1.25 | 0.96 |
| Current assets | | | | |
| Inventories | 9,112.68 | 8,208.25 | 9,100.91 | 8,175.78 |
| Trade receivables | 100.21 | 26.93 | 100.21 | 26.93 |
| Cash and cash equivalents | 421.34 | 390.48 | 421.34 | 390.48 |
| Short term loans and advances | 1,895.86 | 1,014.87 | 1,927.71 | 1,016.31 |
| Other current assets | 6,294.50 | 6,286.87 | 6,245.17 | 6,248.90 |
| Total | 10,994.04 | 10,072.22 | 11,092.81 | 10,149.79 |

2 The above Audited financial results have been reviewed by the Audit, Risk and Controls Committee, approved and taken on record by the Board of Directors in their meeting held on April 29, 2015.

3 The Company operates in one reportable segment in terms of Accounting Standard 17.

4 The figures for the quarters ended March 31, 2015 and March 31, 2014 have been derived as a balancing figures between the amounts as per the annual audited accounts and the year to date unaudited results upto December 31, 2014 and December 31, 2013 respectively.

5 The Board of Directors at their meeting considered and recommended a dividend of Rs. 92.99 lakhs i.e. Rs. 0.50 per share (Nominal value Rs. 10.00 per share) for the financial year 2014-15.

6 In accordance with the requirements of Schedule II to the Companies Act 2013, the Company has re-assessed the useful lives of the fixed assets. Consequent to such change, additional depreciation charge amounting to Rs. 31.86 lacs has been recorded in the statement of profit and loss for the current year and an amount of Rs. 31.58 lakhs (net of deferred tax credit - Rs. 16.26 lakhs) has been charged to the opening retained earnings in respect of assets whose remaining useful life is nil as at April 1, 2014.

7 Previous period figures have been regrouped, wherever considered necessary.

By Order of the Board
 For and on Behalf of Board of Directors


 Raghunath.P
 Whole Time Director

Place: Chennai
 Date: April 29, 2015



PRESS RELEASE

**FORTIS MALAR REPORTS Q4FY15 REVENUE OF RS 30.5 CR, +11%
OPERATING PROFIT FOR THE QUARTER AT RS 2.4 CR,
FY15 CONSOLIDATED REVENUE AT RS 117.9 CR, +9%
CONSOLIDATED OPERATING PROFIT FOR FY15 AT RS 7.5 CR
BOARD RECOMMENDS DIVIDEND OF 5% PER EQUITY SHARE OF RS.10 EACH**

Chennai, April 29, 2015: Fortis Malar Hospitals Limited, a subsidiary of Fortis Healthcare Limited, a leading integrated healthcare delivery service provider in India, today announced its results for the quarter ended March 31, 2015 and for the full year ended March 31, 2015.

Commenting on the results Mr. Daljit Singh, Chairman, Fortis Malar Hospitals Limited, said, “The Company ended the year with strong momentum, resulting from enhanced clinical outcomes and robust financial performance. Led by a very talented team of clinicians, we have occupied the place of pride amongst the top heart transplant centers in the world, whilst strengthening our position in key specialties like Cardiology, Neuro Sciences, Orthopedics, Obstetrics & Gynecology. The Board at its meeting earlier today has recommended a dividend of 5% i.e Rs.0.50 per Equity Share of Rs.10 each, fully paid up. ”

Key financial highlights for Q4 FY2015

- Fortis Malar Hospitals reported operating revenue of Rs 30.46 Cr, a growth of 11% over the corresponding quarter of the previous year.
- Operating profit for the quarter stood at Rs 2.38 Cr compared to Rs.3.15 Cr in the corresponding quarter of the previous year.
- Profit before tax stood at Rs 3.41 Cr compared to Rs 4.22 Cr in the corresponding quarter of last year.
- Net profit during the quarter was at Rs 2.24 Cr compared to Rs.2.79 Cr reported during the corresponding period, last fiscal.

- Fortis Malar’s revenue growth was driven by better performance in Cardiology, CTVS, Renal, Neuro & Spine, General surgery and Cosmetic /Plastic surgery, which grew by 39%, 52%, 18%, 11%, 21% and 41% respectively.

Key financial highlights for FY2015

- Fortis Malar reported consolidated operating revenue for the year ended March 31, 2015 of Rs 117.93 Cr, a growth of 9% over the previous year.
- Consolidated operating profit for the year stood at Rs 7.54 Cr compared to Rs 8.94 Cr in the previous year.
- Profit before tax stood at Rs 11.97 Cr compared to Rs 13.39 Cr in the corresponding quarter of last year.
- Consolidated Net profit for the year was at Rs 7.86 Cr

Operational Highlights for Q4 2015

- During the quarter, the hospital launched an Information and Telemedicine Centre at Dibrugarh, Assam which will facilitate people from North east to consult with super specialist from Fortis Malar for their illness through video conferencing.
- Dr. K.R. Balakrishnan (Director – Cardiac sciences) was honored with “Life time Achievement award” by Rotary International, Tamil Nadu, Chennai and Dr. K.G. Suresh Rao (HOD – Cardiac critical care and Cardiac Anesthesia) was honored with “Excellence award”
- The expert medical team at the hospital continued to perform high risk and rare surgeries. During the quarter, the team performed following surgeries:
 - The cardiology team at Fortis Malar successfully performed eight heart transplants which included an HVAD (Heart ware Ventricular Assist Device) and seven cadaver human heart.
 - The Hospital also performed 17 renal transplants.
 - 18 Knee replacement surgeries and 4 Hip replacement surgeries were also performed at the hospital.

- India's first inter-state Heart & Lung transplants were successfully performed on a 20 years old male patient who had been suffering from congenital VSD and pulmonary hypertension (Eisenmengers syndrome) for whom heart and lung transplant was the only option to survive. The organs for transplant were air lifted from Guntur, Andhra Pradesh.
- Expert Neurologist at Fortis Malar hospital performed a complex 9 hour brain surgery to cure 7 years old's drug resistant epilepsy.
- A team of doctors at Fortis Malar successfully performed a Metabolic – Laparoscopic Mini Gastric Bypass surgery on a 72 years old patient.

Corporate Social Responsibility

Playing its part as a good social corporate citizen, Fortis Malar has been involved in activities that contribute to society. The hospital actively engages with the local community, at a meaningful level and organised:

- Health awareness talks, Health checkups and free Cardiac camps at various corporate and Government organizations
- Free CPR training sessions were organized as part of the Heart saver program at hospital and at various corporate. A special session was also conducted for the benefit of students of Jerusalem college of Engineering, Chennai.
- On the occasion of International Women's Day, a series of activities for women including a special health check package, health talks and an awareness campaign conducted.
- As part of our Community Connect initiative - "Sunday Conversations" with our specialists on topical health issues have been continued during the quarter at the hospital.

About Fortis Malar Hospitals Ltd

Fortis Malar Hospital (formerly known as Malar Hospital) was acquired by Fortis Healthcare (India) Limited in early 2008. The hospital founded in 1992, is established as one of the largest corporate hospitals in Chennai providing quality super specialty and multi specialty healthcare services. Fortis

Malar Hospitals, with 180 beds, focuses on providing comprehensive medical care in the areas of Cardiology and Cardiac Surgery, Neuro Surgery, Gynaecology, Orthopaedics, Gastroenterology, Neurology, Paediatrics, Diabetics, Nephrology and Internal Medicine.

Fortis Malar Hospital has a state of the art Cath Lab and multiple dedicated cardiac operation theatres and intensive coronary care units. Several rare and complex Adult and Paediatric Cardiac surgeries, Orthopedic and Joint replacements, Neurosurgeries and Plastic reconstruction surgeries have been performed at this hospital. The hospital's Obstetrics and Gynaecology services are among the busiest in the city, successfully performing many complicated deliveries and surgeries. They are supported by a dedicated Neonatology unit.

About Fortis Healthcare Ltd

Fortis Healthcare Limited is a leading integrated healthcare delivery service provider in India. The healthcare verticals of the company primarily comprise hospitals, diagnostics and day care specialty facilities. Currently, the company operates its healthcare delivery services in India, Singapore, Dubai, Mauritius and Sri Lanka with 54 healthcare facilities (including projects under development), approximately 10,000 potential beds and 260 diagnostic centres. In a global study of the 30 most technologically advanced hospitals in the world, its flagship, the Fortis Memorial Research Institute' (FMRI), was ranked No.2, by 'topmastersinhealthcare.com, and placed ahead of many other outstanding medical institutions in the world.

DISCLAIMER

This press release may contain forward-looking statements based on the currently held beliefs and assumptions of the management of the Company, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of the Company results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. Given these risks, uncertainties and other factors, recipients of this press release are cautioned not to place undue reliance on these forward-looking statements. The Company assumes no responsibility to publicly amend, modify or revise any forward looking statements, on the basis of any subsequent development, information or events, or otherwise. The information contained herein is subject to change without notice and past performance is not indicative of future results. The Company may alter, modify or otherwise change in any manner the content of this press release, without obligation to notify any person of such revision or changes.

FOR MORE INFORMATION PLEASE CONTACT

Ms. P.S. Ramya Gourri
Executive PR & Communications
Fortis Malar Hospitals Ltd
Mobile: 8939831218
ramya.gourri@fortishealthcare.com

Sumit Jain
K2 Communications Pvt Ltd
Mobile: 9886021715
Sumit.jain@k2communications.in